A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Infigratinib (Primary)
Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cholangiocarcinoma; Lung cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Novartis; Novartis Pharmaceuticals

02 Mar 2021 Results of a retrospective study assessing clinical benefit of FGFR inhibition from four clinical studies: NCT01703481, NCT01004224, NCT02052778 and NCT02924376 presented at the 19th International Congress on Targeted Anticancer Therapies
31 May 2020 Results (n=67) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
29 May 2020 According to a BridgeBio Pharma media release, results from this study will be presented at the ASCO2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com